ASCOT shows that the survival benefit of adjuvant S-1 after BTC surgery remained durable with longer follow-up.
#GIOncology #BiliaryTractCancer #ClinicalEvidence #Gastroenterology #MedSky

ASCOT shows that the survival benefit of adjuvant S-1 after BTC surgery remained durable with longer follow-up.
#GIOncology #BiliaryTractCancer #ClinicalEvidence #Gastroenterology #MedSky
Join Prof. Van K. Morris (MD Anderson) and Prof. David Tougeron (Poitiers University Hospital) live on September 22, 5:00 PM CEST - 90 minutes, live Q&A, in English. Free registration for clinicians: